Associated Papers
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
RET kinase inhibitors for RET-altered thyroid cancers.
Vodopivec DM et al.
Therapeutic Advances in Medical Oncology, 2022
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2017
Select a paper to view details